# Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali

> **NCT04329104** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 348 (actual)

## Conditions studied

- Plasmodium Falciparum Infection
- Malaria

## Interventions

- **BIOLOGICAL:** VRC-MALMAB0100-00-AB (CIS43LS)
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT04329104
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2022-01-26
- **Final completion:** 2023-07-05
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2025-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329104, "Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04329104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*